Cargando…

Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma

IMPORTANCE: Melanoma treatment has evolved during the past decade with the adoption of adjuvant and palliative immunotherapy and targeted therapies, with an unclear impact on health care costs and outcomes in routine practice. OBJECTIVE: To examine changes in health care costs, overall survival (OS)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bateni, Sarah B., Nguyen, Paul, Eskander, Antoine, Seung, Soo Jin, Mittmann, Nicole, Jalink, Matthew, Gupta, Arjun, Chan, Kelvin K. W., Look Hong, Nicole J., Hanna, Timothy P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483386/ https://www.ncbi.nlm.nih.gov/pubmed/37672282 http://dx.doi.org/10.1001/jamadermatol.2023.3179

Ejemplares similares

Changes in healthcare costs and survival in the era of immunotherapy and targeted systemic therapy for melanoma.
por: Nguyen, Paul, et al.
Publicado: (2022)

Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016
por: Brastianos, Harry C., et al.
Publicado: (2020)

Survival in melanoma brain metastases in the era of novel systemic therapies
por: Merola, Joseph P, et al.
Publicado: (2020)

Immunotherapy in the Precision Medicine Era: Melanoma and Beyond
por: Su, Mack Y., et al.
Publicado: (2016)

Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US
por: Moyers, Justin T., et al.
Publicado: (2020)

Timeliness and Modality of Treatment for New Cancer Diagnoses During the COVID-19 Pandemic in Canada
por: Fu, Rui, et al.
Publicado: (2023)

Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy
por: Vasudevan, Harish N., et al.
Publicado: (2023)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada
por: Habbous, Steven, et al.
Publicado: (2022)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Healthcare and Cancer Treatment Costs of Breast Screening Outcomes among Higher than Average Risk Women
por: Mittmann, Nicole, et al.
Publicado: (2023)

Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy
por: Teterycz, Pawel, et al.
Publicado: (2020)

A case report: metastasis of melanoma to the heart in an era of immunotherapy
por: Poulsen, Christian B, et al.
Publicado: (2019)

No Overall Survival Difference in the Immunotherapy Era for Rare Subtypes of Melanoma
por: Safi, Mohammed, et al.
Publicado: (2021)

Cost-effective Analysis of Subcutaneous vs Sublingual Immunotherapy From the Payor’s Perspective
por: Hardin, Frances Mei, et al.
Publicado: (2021)

Melanoma inhibitory activity in Brazilian patients with cutaneous melanoma
por: Odashiro, Macanori, et al.
Publicado: (2015)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

Impact of smoking on health system costs among cancer patients in a retrospective cohort study in Ontario, Canada
por: Isaranuwatchai, Wanrudee, et al.
Publicado: (2019)

Dermoscopic features of thin melanomas: a comparative study of melanoma in situ and invasive melanomas smaller than or equal to 1mm()
por: da Silva, Vanessa Priscilla Martins, et al.
Publicado: (2013)

Does early palliative identification improve the use of palliative care services?
por: Mittmann, Nicole, et al.
Publicado: (2020)

Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis
por: Shaker, Marcus, et al.
Publicado: (2019)

Septoplasty Training During the COVID-19 Era: Development and Validation of a Novel Low-Cost Simulation Model
por: Rosenbaum, Andrés, et al.
Publicado: (2022)

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
por: Lamba, Nayan, et al.
Publicado: (2022)

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
por: Dai, Wei Fang, et al.
Publicado: (2020)

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management
por: Simeone, Ester, et al.
Publicado: (2019)

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
por: Bhave, Prachi, et al.
Publicado: (2023)

Prognostic factors for metastasis in cutaneous melanoma
por: Cherobin, Ana Carolina Figueiredo Pereira, et al.
Publicado: (2018)

Using Real-World Data to Determine Health System Costs of Ontario Women Screened for Breast Cancer
por: Mittmann, Nicole, et al.
Publicado: (2022)

Impact of aggressive management and palliative care on cancer costs in the final month of life
por: Cheung, Matthew C., et al.
Publicado: (2015)

Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
por: Cai, Chao, et al.
Publicado: (2021)

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
por: Leeneman, Brenda, et al.
Publicado: (2020)

Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition
por: Travis, Roman L., et al.
Publicado: (2020)

Stereotactic radiosurgery for melanoma brain metastases: dose-size response relationship in the era of immunotherapy
por: Yusuf, Mehran, et al.
Publicado: (2021)

Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies
por: Stevenson, Valentina B., et al.
Publicado: (2023)

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy
por: Watson, Alexander S., et al.
Publicado: (2022)

Dermoscopic and clinical features of head and neck melanoma
por: Cengiz, Fatma Pelin, et al.
Publicado: (2015)

Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials
por: Cheung, Matthew C, et al.
Publicado: (2021)

Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies
por: Li, SiNi, et al.
Publicado: (2021)

A melanoma risk score in a Brazilian population
por: Bakos, Lucio, et al.
Publicado: (2013)

Cost-effectiveness of Artificial Intelligence as a Decision-Support System Applied to the Detection and Grading of Melanoma, Dental Caries, and Diabetic Retinopathy
por: Gomez Rossi, Jesus, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sns1jmcqoibi2id5vqjtr1pkaa